OBJECTIVES: The high cost of contemporary cancer treatments have raised budgetary concern. The study aims to examine the trend of cancer related medical spending in the US. METHODS: Using nationally representative data from the Medical Expenditure Panel Survey in years 2000 to 2013(N = 479,499), we estimated the trend of the annual medical utilization and expenditures attributed to cancer in cancer patients during this period. A two-part model was used to estimate annual medical expenditures and a zero-inflated Poisson model was used to estimate the number of outpatient visits, hospital admissions, and prescription drugs taken for persons with and without cancer. Excess expenditures and utilizations attributable to cancer were calculated as the incremental effects of cancer in the models. All costs are presented in 2013 dollar. RESULTS: In year 2000, the cost difference between persons with and without cancers was $10,300 (unadjusted) per year. It increased to $12,100 in 2005 and continuously declined to $9,900 in 2013. After adjusting the patient-level differences and general secular trend, cancer-attributable spending was $8,700 in 2000, $10,100 in 2005, and $9,500 in 2013. Among the total annual spending, hospitalization, outpatient and prescription medications account for 34%, 48% and 13% respectively. The shares remained virtually unchanged during the study period. The number of hospitalization and outpatient visits per patient decreased by 28% and 29%, but the unit cost increased by $976 and $912 respectively. In contrast, the unit cost of prescription medication encounter increased by $32. CONCLUSIONS:  Contrast with the general growing trend, cancer-attributable medical spending has remained stable in the past decade, or even declined in recent years. There is also little change in the shares of different cost components. However the unit costs of inpatient and outpatient services have increased substantially.